Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study

Trial Profile

Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Anastrozole; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BOOSTER
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Mar 2017 Planned End Date changed from 30 Jun 2017 to 1 Jun 2019.
    • 06 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top